Aeon Global Health (OTCMKTS:AGHC) and Natera (NASDAQ:NTRA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

Earnings & Valuation

This table compares Aeon Global Health and Natera’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aeon Global Health $16.30 million 0.13 -$8.00 million ($1.15) -0.19
Natera $257.65 million 5.00 -$128.15 million ($2.15) -9.48

Aeon Global Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Aeon Global Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aeon Global Health and Natera’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aeon Global Health -29.16% -290.44% -38.31%
Natera -49.72% -790.13% -51.80%

Insider and Institutional Ownership

88.2% of Natera shares are owned by institutional investors. 11.5% of Aeon Global Health shares are owned by company insiders. Comparatively, 13.2% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Aeon Global Health and Natera, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aeon Global Health 0 1 0 0 2.00
Natera 0 1 6 0 2.86

Natera has a consensus target price of $28.43, suggesting a potential upside of 39.42%. Given Natera’s stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Aeon Global Health.

Volatility and Risk

Aeon Global Health has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, Natera has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Summary

Natera beats Aeon Global Health on 8 of the 14 factors compared between the two stocks.

About Aeon Global Health

Aeon Global Health Corp., together with its subsidiaries, provides various clinical laboratory testing services in the United States. The company operates through Laboratory Testing Services and Web-Based Software segments. Its laboratory testing services include the testing of an individual's blood, urine, or saliva for the presence of drugs or chemicals, as well as the patient's DNA profile. The company primarily offers medical toxicology, DNA pharmacogenomics, cancer genetic testing, and molecular biology tests. It also provides Web-based services as software as a service for Web-based revenue cycle management applications; and telehealth products and services that enable healthcare organizations to coordinate care for patients, and enhance related administrative and clinical workflows, as well as compliance with regulatory requirements. In addition, AEON Global Health Corp. offers post contract customer support services. The company was formerly known as Authentidate Holding Corp. and changed its name to Aeon Global Health Corp. in January 2018. Aeon Global Health Corp. is headquartered in Gainesville, Georgia.

About Natera

Natera, Inc., a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the United States and internationally. Natera, Inc. has collaboration partnership with Fox Chase Cancer Center to assess customized circulating tumor DNA assay for recurrence monitoring of kidney cancer; and clinical trial collaboration with Neon Therapeutics, Inc. to assess the treatment response to personal cancer vaccine. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

Receive News & Ratings for Aeon Global Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeon Global Health and related companies with MarketBeat.com's FREE daily email newsletter.